26673-30-3

Basic information

• Product Name: 5-Chloro-1-tetralone
• Synonyms: 5-Chloro-1-tetralone;5-Chloro-α-Tetralone;5-chloro-3,4-dihydronaphthalen-1(2H)-one;5-Chloro-tetral-1-on;5-Chloro-3,4-dihydronaphthalen-1(2H)
• CAS NO: 26673-30-3
• Molecular Formula: C₁₀H₉ClO
• Molecular Weight: 180.63086
• Mol File: 26673-30-3.mol

Chemical Properties

• Melting Point: 65.5-67 °C
• Boiling Point: 306.151 °C at 760 mmHg
• Flash Point: 145.805 °C
• Appearance: /
• Density: 1.248 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Chloro-1-tetralone(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chloro-1-tetralone(26673-30-3)
• EPA Substance Registry System: 5-Chloro-1-tetralone(26673-30-3)

Safety Data

• Hazardous Substances Data: 26673-30-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Chloro-1-tetralone is used as a key intermediate in the synthesis of various drugs and pharmaceuticals. Its reactivity and versatility allow for the creation of a wide range of drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Chloro-1-tetralone serves as a precursor in the production of various agrochemicals. Its unique chemical properties enable the development of effective compounds for use in agriculture, such as pesticides and herbicides.
Used in Organic Chemistry Research:
5-Chloro-1-tetralone is utilized as a valuable intermediate in the field of organic chemistry research. Its distinct properties make it an ideal candidate for the exploration of new chemical reactions and the synthesis of novel organic compounds.
Used in Drug Development:
As a building block in the development of new drug candidates, 5-Chloro-1-tetralone plays a crucial role in the discovery and design of innovative pharmaceuticals. Its unique structure and reactivity contribute to the creation of molecules with potential therapeutic benefits.
Used in Synthesis of Biologically Active Molecules:
5-Chloro-1-tetralone is employed in the synthesis of various biologically active molecules, including those with potential applications in medicine, agriculture, and other industries. Its versatility and reactivity make it a valuable component in the development of compounds with significant biological activity.

InChI:InChI=1/C10H9ClO/c11-9-5-1-4-8-7(9)3-2-6-10(8)12/h1,4-5H,2-3,6H2

Upstream product

• 68449-31-0 4-(2-chlorophenyl)butanoic acid 
• 90401-68-6 5-Amino-3,4-dihydro-2H-naphthalen-1-one; hydrochloride 
• 96-48-0 4-butanolide 
• 108-90-7 chlorobenzene 
• 22991-05-5 4-(3-chlorophenyl)-butyric acid 
• 62903-14-4 4-(3-chlorophenyl)-4-oxobutyric acid 
• 51114-94-4 (2-carboxyethyl)triphenylphosphonium bromide 
• 529-34-0 3,4-dihydronaphthalene-1(2H)-one 
• 51114-73-9 5-nitro-1-tetralone 
• 41823-28-3 5-amino-3,4-dihydronaphthalen-1(2H)-one 

Downstream Products

• 101440-90-8 8-chloro-4-o-tolyl-1,2-dihydro-naphthalene 
• 101876-57-7 5-chloro-1-(2-methoxy-phenyl)-1,2,3,4-tetrahydro-[1]naphthol 
• 20816-76-6 5-chloro-1-naphthalenol 
• 101446-33-7 1-chloro-5-o-tolyl-naphthalene 
• 90400-98-9 C₁₇H₁₆ClNO₃S 
• 530093-85-7 2-(5-chloro-3,4-dihydro-1-naphthalenyl)ethyl-4-methylphenylsulphonate 
• 779310-74-6 8-(5-chloro-1,2,3,4-tetrahydro-naphthalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one 

Relevant articles and documents

NAPTHOQUINONES, PRO-DRUGS, AND METHODS OF USE THEREOF

Provided herein are naphthoquinones compounds such as those with a hydrogen bond donating group of the formula (I): wherein: R1, R2, R3, R4, R5, and n are as defined herein. Also provided herein are pharmaceutical composition of the present compounds and methods of treatment using the compounds including their use in the treatment of cancer.

Highly enantioselective [3+2] coupling of cyclic enamides with quinone monoimines promoted by a chiral phosphoric acid

Enantioselective [3+2] coupling of cyclic enamides with quinone monoimines was realised using a chiral phosphoric acid as a catalyst. This transformation allowed for the synthesis of highly enantioenriched polycyclic 2,3-dihydrobenzofurans (up to 99.9% ee). The absolute configuration of one product was determined by an X-ray crystal structural analysis. We also found a possible mechanism for this reaction.

Enantioselective halogenative semi-pinacol rearrangement: Extension of substrate scope and mechanistic investigations

The present Full Paper article discloses a survey of our recent results obtained in the context of the enantioselective halogenation-initiated semi-pinacol rearrangement. Commencing with the fluorination/semi-pinacol reaction first and moving to the heavier halogens (bromine and iodine) second, the scope and limitations of the halogenative phase-transfer methodology will be discussed and compared. An extension of the fluorination/semi-pinacol reaction to the ring-expansion of five-membered allylic cyclopentanols will be also described, as well as some preliminary results on substrates prone to desymmetrization will be given. Finally, the present manuscript will culminate with a detailed mechanistic investigation of the canonical fluorination/semi-pinacol reaction. Our mechanistic discussion will be based on in situ reaction progress monitoring, complemented with substituent effect, kinetic isotopic effect and non-linear behaviour studies.

Enantioselective organocatalytic fluorination-induced Wagner-Meerwein rearrangement

Cracked under strain: Strained allylic cyclobutanols and cyclopropanols readily undergo a ring expansion described by the title rearrangement. This reaction is promoted by catalytic amounts of 1 and displays high tolerance with respect to the substrate scope. The corresponding β-fluoro spiroketone products are isolated in high yields and with excellent stereoselectivities. EDG=electron-donating group, EWG=electron-withdrawing group. Copyright

SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS

Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.

Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands

A series of N-substituted analogs based upon the spiropiperidine core of 1 was synthesized and exhibited high binding affinity to the nociceptin (NOP) receptor. The selectivities against other known opioid receptors were determined.

Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II

A compound which is a benzo[a]phenazine-11-carboxamide derivative of formula (I) wherein each of R1 to R4, which are the same or different, is selected from hydrogen, halogen, hydroxyl, C1-C6 alkoxy which is unsubstituted or substituted, heteroaryloxy, C1-C6 alkyl which is unsubstituted or substituted, nitro, cyano, azido, amidoxime, CO2R10, CON(R12)2, OCON(R12), SR10, SOR11, SO2(R11), SO2N(R12)2, N(R12)2, NR10SO2R11, N(SO2R11)2NR10(CH2)nCN, NR10COR11, OCOR11 or COR10; each of R5 to R7, which are the same or different, is selected from hydrogen, halogen, hydroxy, C1-C6 alkoxy, C1-C6 alkyl, SR10 and N(R12)2; Q is C1-C6 alkylene which is unsubstituted or substituted by (i) C1-C6 alkyl which is unsubstituted or substituted, (ii) hydroxy, provided that the hydroxy group is not, to either of the N atoms adjacent to Q in formula (I), (iii) CO2R10, or (iv) CON(R12); R1 and R9, which are the same or different, are each hydrogen or C1-C6 alkyl, or R8 and R9 together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered N-containing heterocyclic ring which may include one additional heteroatom selected from O, N and S, or one of R8 and R9 is an alkylene chain optionally interrupted by O, N or S, which is attached to a carbon atom on the alkylene chain represented by Q to complete a saturated 5- or 6-membered N-containing heterocyclic ring as defined above; or a pharmaceutically acceptable salt thereof; with the proviso that at least one R1 to R4 is other than hydrogen. These compounds are inhibitors of topoisomerase I and/or topoisomerase II and can be used to treat tumours, including tumours which express MDR.